Evidence map›Paper›PMID 40769726›Full record

Trial reportAJNR. American journal of neuroradiology2026

MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial.

Hui Chen, Maarten Lansberg, Guangming Zhu, Christy Cassarly, Qi Paula, Stephanie Kemp, George Howard, Eric E Smith, David Tirschwell, Kevin N Sheth and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AJNR. American journal of neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hui ChenFrom the Department of Neuroradiology (H.C., M.W.), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4479-0185
Maarten LansbergStanford Stroke Center (M.L., S.K.), Palo Alto, California.ORCID 0000-0002-3545-6927
Guangming ZhuDepartment of Neurology (G.Z.), The University of Arizona, Tucson, Arizona.ORCID 0000-0001-5519-3135
Christy CassarlyDepartment of Public Health Sciences (C.C., Q.P.), Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-0304-9833
Qi PaulaDepartment of Public Health Sciences (C.C., Q.P.), Medical University of South Carolina, Charleston, South Carolina.
Stephanie KempStanford Stroke Center (M.L., S.K.), Palo Alto, California.ORCID 0000-0002-2804-6495
George HowardDepartment of Biostatistics (G.H.), School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Eric E SmithDepartment of Clinical Neurosciences and Hotchkiss Brain Institute (E.E.S.), University of Calgary, Calgary, Alberta, Canada.
David TirschwellDepartment of Neurology (D.T.), Harborview Medical Center, University of Washington School of Medicine, Seattle, Washington.ORCID 0000-0002-8059-2901
Kevin N ShethCenter for Brain & Mind Health (K.N.S.), Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-2003-5473
Hooman KamelDepartment of Neurology (H.K.), Cornell University, Ithaca, New York.ORCID 0000-0002-5745-0307
William T LongstrethDepartment of Neurology (W.T.L.), School of Medicine, and Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.
Mitchell S V ElkindDepartment of Neurology (M.S.V.E.), Vagelos College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Joseph BroderickUniversity of Cincinnati Gardner Neuroscience Institute (J.B.), University of Cincinnati, Cincinnati, Ohio.
Ronald M LazarDepartment of Neurology (R.M.L.), UAB Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-7388-042X
Max WintermarkFrom the Department of Neuroradiology (H.C., M.W.), The University of Texas MD Anderson Cancer Center, Houston, Texas max.wintermark@gmail.com.ORCID 0000-0002-6726-3951

Funding

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenicstroke (ARCADIA)U01NS095869 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRODERICK, JOSEPH PAUL, KAMEL, HOOMAN · 2017 to 2022
$22.0M
Workshop to Identify Collaborative Project(s) for the NIH StrokeNet and the Japan NEtwork for Clinical Stroke Trials (NECST)U01NS087748 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Catherine R. Dillon, Jordan J. Elm · 2014 to 2026
$14.1M
ARCADIA CSI (Cognition and Silent Infarcts)U01NS110728 · NINDS · STANFORD UNIVERSITY · PI LANSBERG, MAARTEN G, LAZAR, RONALD M · 2019 to 2023
$5.4M
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials NetworkU24NS107220 · NINDS · STANFORD UNIVERSITY · PI MAARTEN G LANSBERG · 2018 to 2026
$2.8M
NINDS NIH HHS U01 NS087748NINDS NIH HHS U01 NS095869NINDS NIH HHS U01 NS110728NINDS NIH HHS U24 NS107220
6 · The paper itself

Abstract

background and purposeThe ARCADIA-MRI study, an ancillary study to the randomized Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, reported that the risk of incident nonlacunar covert infarcts was lower in the apixaban group than in the aspirin group. This article presents the additional, prespecified, exploratory outcomes beyond the primary article, specifically examining the effect of apixaban on hemorrhagic lesions on MRI. MATERIALS AND

methodsThe ARCADIA-MRI study was conducted in conjunction with ARCADIA trial visits, with follow-up durations ranging from 4 months to 5.3 years (median, 27 months). It included randomized patients who were eligible for cognitive testing and lacked MRI contraindications. Two experienced raters, blinded to treatment assignments, independently evaluated the baseline and follow-up MRI scans. The radiologic end points of this analysis were incident intracranial hemorrhage (>10 mm), microbleeds (≤10 mm), and superficial siderosis.

resultsMRI outcomes were compared between the 79 patients in the apixaban group and 95 in the aspirin group with both baseline and follow-up MRIs available. The treatment groups had similar baseline MRI findings. On the follow-up MRIs, the findings of incident bleeding events were similar between the treatment groups (all,

conclusionsIn an exploratory analysis of the ARCADIA-MRI substudy, MRI findings of incident bleeding events were similar in patients randomized to receive apixaban and aspirin.

Indexed as

AspirinIntracranial HemorrhagesMagnetic Resonance ImagingPyrazolesPyridonesAgedFactor Xa InhibitorsFemaleHumansMaleMiddle AgedapixabanAspirinFactor Xa InhibitorsPyrazolesPyridones

Identifiers

PMID40769726
PMCPMC12549002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.